At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 43 enrolled
Drug / intervention
Regorafenib 160 mgdrug
Likely dose
Regorafenib 160 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase II Study Evaluating the Efficacy and the Safety of Regorafenib in Patients Aged More Than 70 Years Old With a Metastatic Colorectal Adenocarcinoma .
Federation Francophone de Cancerologie Digestive·interventional·Posted Jun 2, 2016·Updated Feb 23, 2024
In Brief
A Phase 2 clinical trial evaluating Regorafenib 160 mg for Colorectal Adenocarcinoma. Completed, enrolled 43 participants across 16 sites.
Detailed Summary
Multicenter prospective phase II study evaluating regorafenib in older patients with metastatic colorectal cancer
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsColorectal Adenocarcinoma
CountriesFrance
Collaborators--
Timeline
Phase 2CompletedFinished
20162017201820192020202120222023202420252026
Enrollment StartJan 2016
First PostedJun 2016
Primary CompletionAug 2017
Study CompletionSep 2017
TodayJul 2026
First PostedJun 2, 2016
Enrollment StartJan 1, 2016
Primary CompletionAug 1, 2017
Study CompletionSep 1, 2017
TodayJul 2, 2026
Enrollment to primary: 1.6 yearsPosted 10.1 years ago
Interventions
Regorafenib 160 mgdrug